Frequent cystoscopy for monitoring nonmuscle-invasive bladder cancer (NMIBC) is burdensome and costly, prompting a search for alternatives.

Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.

The Food and Drug Administration (FDA) has granted Priority Review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder ...

An expert discusses how recent updates to AUA, EAU and NCCN guidelines have cautiously shifted toward more bladder-sparing approaches for BCG-unresponsive patients, incorporating new FDA-approved ...

The FDA has granted RMAT designation to detalimogene voraplasmid for the treatment of high-risk, BCG-unresponsive, NMIBC with CIS.

Normally, the sphincter remains closed as the bladder fills with urine. The weakened muscles and relaxed pelvic floor have ...

There is limited research on chronic pelvic pain in men, which delays treatment for male patients experiencing symptoms of ...

This is kind of embarrassing, but, for a while, I’ve been leaking urine. Can something be done to fix this incontinence ...

Bladder cancer symptoms often go unnoticed until it's too late. Learn the warning signs most people ignore and how early ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the ...